Ajit Dash
- Hepatology top 5%
- Liver physiology and pathology 6
- Immunology top 10%
- IL-33, ST2, and ILC Pathways 6
- Immunology and Allergy top 5%
- Pharmacology top 5%
- Drug-Induced Hepatotoxicity and Protection 5
- Physiology top 10%
-
- Liver Disease Diagnosis and Treatment 6
-
- Pancreatitis Pathology and Treatment 4
-
- 3D Printing in Biomedical Research 4
-
- Monoclonal and Polyclonal Antibodies Research 4
-
- Drug Transport and Resistance Mechanisms 3
- Co-authors
- Mark B. PepysBrian R. WamhoffE. A. MunnM B PepysA. FeinsteinRyan E. FeaverAviva PetrieNeil Richardson
- Journals
- Expert Opinion on Drug Metabolism & Toxicology (3 papers)Journal of Allergy and Clinical Immunology (2 papers)Drug Safety (2 papers)
- Partner nations
- United StatesUnited KingdomGermany
In The Last Decade
Ajit Dash
36 papers receiving 1.6k citations
Hit Papers
Peers
Comparison fields: 5 of 107
- Hepatology 272
- Immunology 360
- Immunology and Allergy 90
- Pharmacology 129
- Physiology 360
Countries citing papers authored by Ajit Dash
This map shows the geographic impact of Ajit Dash's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ajit Dash with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ajit Dash more than expected).
Fields of papers citing papers by Ajit Dash
This network shows the impact of papers produced by Ajit Dash. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ajit Dash. The network helps show where Ajit Dash may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Ajit Dash, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 0 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 4 | |
| 4 | 2024 | 1 | |
| 5 | 2024 | 2 | |
| 6 | 2023 | 13 | |
| 7 | 2022 | 43 | |
| 8 | 2022 | 24 | |
| 9 | Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trialbreakdown → | 2021 | 195 |
| 10 | 2020 | 24 | |
| 11 | 2016 | 29 | |
| 12 | 2015 | 13 | |
| 13 | 2015 | 27 | |
| 14 | 2013 | 91 | |
| 15 | 2012 | 16 | |
| 16 | 2009 | 8 | |
| 17 | 2009 | 127 | |
| 18 | Comparative clinical study of protein SAP (amyloid P component) and C-reactive protein in serum. | 1978 | 166 |
| 19 | 1977 | 73 | |
| 20 | 1976 | 4 |
About Ajit Dash
Ajit Dash is a scholar working on Hepatology, Pharmacology and Immunology, having authored 38 papers that have together received 1.8k indexed citations. Recurring topics across this work include Liver physiology and pathology (6 papers), Liver Disease Diagnosis and Treatment (6 papers), IL-33, ST2, and ILC Pathways (6 papers), Drug-Induced Hepatotoxicity and Protection (5 papers), Pancreatitis Pathology and Treatment (4 papers), 3D Printing in Biomedical Research (4 papers), Monoclonal and Polyclonal Antibodies Research (4 papers) and Drug Transport and Resistance Mechanisms (3 papers). The work is most often cited by research in Hepatology (272 citations), Immunology (360 citations) and Immunology and Allergy (90 citations). Ajit Dash has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Mark B. Pepys, Brian R. Wamhoff, E. A. Munn, M B Pepys, A. Feinstein, Ryan E. Feaver, Aviva Petrie, Neil Richardson, Thelma C. Fletcher and Banumathi K. Cole. Their work appears in journals such as Expert Opinion on Drug Metabolism & Toxicology, Journal of Allergy and Clinical Immunology, Drug Safety, Clinical Gastroenterology and Hepatology and Gut.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.